Updated on 2024/11/05

写真a

 
MAEDA Keiko
 
Organization
Nagoya University Hospital Gastroenterology Assistant Professor
Graduate School
Graduate School of Medicine
Title
Assistant Professor

Degree 1

  1. 博士(医学) ( 2016.4   名古屋大学 ) 

Research Areas 2

  1. Life Science / Gastroenterology

  2. Life Science / Gastroenterology

Research History 2

  1. 名古屋大学医学部附属病院

    2018.4

      More details

    Country:Japan

  2. Boston Children's Hospital

    2016.6 - 2018.3

Professional Memberships 4

  1. 日本内科学会

  2. 日本消化器内視鏡学会

  3. 日本消化器病学会

  4. 日本炎症性腸疾患学会

Awards 5

  1. 学術奨励賞

    2023.6   日本女医会  

  2. 日本炎症性腸疾患学会-アッヴィ研究奨励賞

    2023.2   日本炎症性腸疾患学会  

  3. 令和4年度 医学系研究科医学奨励賞 最優秀賞

    2023.1   名古屋大学  

  4. Early career investigator award

    2018.6  

     More details

    Award type:Award from international society, conference, symposium, etc.  Country:United States

  5. Poster of distinction award

    2017.5  

     More details

    Award type:International academic award (Japan or overseas)  Country:United States

 

Papers 86

  1. Initial Tumor Size and Narrow-Band Image Findings Estimate Growth Speed in Duodenal Tumors. Reviewed International journal

    Takashi Hirose, Naomi Kakushima, Yoshiyuki Minami, Satoshi Furune, Eri Ishikawa, Tsunaki Sawada, Keiko Maeda, Takeshi Yamamura, Kazuhiro Furukawa, Masanao Nakamura, Masato Nakaguro, Hiroki Kawashima

    Digestive diseases (Basel, Switzerland)     page: 1 - 10   2024.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: Recently, the detection of superficial non-ampullary duodenal epithelial tumors (SNADETs) including adenomas and superficial duodenal carcinomas has increased. Various endoscopic treatment methods have also been reported for SNADETs, but there are few reports on the natural history. The aim of this study was to analyze factors related to tumor growth and determine the characteristics of SNADETs which need early therapeutic intervention. METHODS: A single-center, retrospective study was performed on the medical records of 309 patients with SNADETs who underwent endoscopic or surgical resection between January 2010 and May 2021. Of these, 41 patients who were followed up for more than 1 year by endoscopy were analyzed. The primary outcome was an analysis of the tumor growth speed. Secondary outcomes were the relationship between the tumor growth speed and mucin phenotype, tumor size and findings of magnifying endoscopy with narrow-band imaging (M-NBI). RESULTS: The observation period was 24 months (13-182). Tumor growth speed was 1.1 mm/year (0-21.6). Tumor diameter ≥10 mm at first detection (p = 0.004; odds ratio 19.5 [2.03-186.96]) and mixed type by M-NBI (p = 0.036; odds ratio 9.69 [1.05-89.88]) were identified as risk factors of tumors growing at a rate of ≥3 mm/year. There was no statistically significant difference in the speed of tumor growth between the different mucin immunohistochemical phenotypes. CONCLUSION: Initial tumor size and findings of M-NBI are useful to predict tumor growth and consider early intervention.

    DOI: 10.1159/000540544

    PubMed

  2. Artificial intelligence-based diagnostic imaging system with virtual enteroscopy and virtual unfolded views to evaluate small bowel lesions in Crohn's disease. Reviewed International journal

    Kazuhiro Furukawa, Masahiro Oda, Osamu Watanabe, Masanao Nakamura, Takeshi Yamamura, Keiko Maeda, Kensaku Mori, Hiroki Kawashima

    Revista espanola de enfermedades digestivas     2024.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Since even subtle mucosal changes may be depicted using virtual endoscopy created by the three-dimensional reconstruction of MDCT images, we developed a novel diagnostic imaging system that integrates and displays virtual enteroscopy, curved planar reconstruction, and a virtual unfolded view, the width of which changes with increases/decreases in the inner luminal diameter. The system is also equipped with artificial intelligence that superimposes and displays depressed areas, generates an automatic small bowel centerline that connects fragmented small bowel regions, and performs electronic cleansing. We retrospectively evaluated the diagnostic performance of this system for small bowel lesions in Crohn's disease, which were divided into two groups: endoscopically-observable and endoscopically-unobservable. Lesion detection rates for stenoses, longitudinal ulcers with a cobblestone appearance, and scars were excellent in both groups. This system, when used in combination with endoscopy, shows slight mucosal changes in areas in which an endoscope cannot reach due to strictures, thereby extending the range of observation of the small bowel. This system is a useful diagnostic modality that has the capacity to assess mucosal healing and provide extraluminal information.

    DOI: 10.17235/reed.2024.10405/2024

    PubMed

  3. Reply: Interleukin-18 Inhibition in Inflammatory Bowel Diseases: A Delicate Balance.

    Maeda K, Kawashima H

    Inflammatory bowel diseases     2024.3

     More details

    Language:English  

    DOI: 10.1093/ibd/izae039

    PubMed

  4. Risk factors for rebleeding in gastroduodenal ulcers. International journal

    Nobuhito Ito, Kohei Funasaka, Toshihisa Fujiyoshi, Kazuki Nishida, Yusuke Satta, Kazuhiro Furukawa, Naomi Kakushima, Satoshi Furune, Eri Ishikawa, Yasuyuki Mizutani, Tsunaki Sawada, Keiko Maeda, Takuya Ishikawa, Takeshi Yamamura, Eizaburo Ohno, Masanao Nakamura, Ryoji Miyahara, Yoji Sasaki, Jun-Ichi Haruta, Mitsuhiro Fujishiro, Hiroki Kawashima

    Irish journal of medical science   Vol. 193 ( 1 ) page: 173 - 179   2024.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Rebleeding after hemostasis of the gastroduodenal ulcer (GDU) is one of the indicators associated with death among GDU patients. However, there are few studies on risk score that contribute to rebleeding after endoscopic hemostasis of bleeding peptic ulcers. AIMS: The aim of this study was to identify factors associated with rebleeding, including patient factors, after endoscopic hemostasis of bleeding gastroduodenal ulcers and to stratify the risk of rebleeding. METHODS: We retrospectively enrolled 587 consecutive patients who were treated for Forrest Ia to IIa bleeding gastroduodenal ulcers with endoscopic hemostasis at three institutions. Risk factors associated with rebleeding were assessed using univariate and multivariate logistic regression analyses. The Rebleeding Nagoya University (Rebleeding-N) scoring system was developed based on the extracted factors. The Rebleeding-N score was internally validated using bootstrap resampling methods. RESULTS: Sixty-four patients (11%) had rebleeding after hemostasis of gastroduodenal ulcers. Multivariate logistic regression analysis revealed four independent rebleeding risk factors: blood transfusion, albumin <2.5, duodenal ulcer, and diameter of the exposed vessel ≧2 mm. Patients with 4 risk factors in the Rebleeding-N score had a 54% rebleeding rate, and patients with 3 risk factors had 44% and 25% rebleeding rates. In the internal validation, the mean area under the curve of the Rebleeding-N score was 0.830 (95% CI = 0.786-0.870). CONCLUSIONS: Rebleeding after clip hemostasis of bleeding gastroduodenal ulcers was associated with blood transfusion, albumin <2.5, diameter of the exposed vessel ≧2 mm, and duodenal ulcer. The Rebleeding-N score was able to stratify the risk of rebleeding.

    DOI: 10.1007/s11845-023-03450-2

    Web of Science

    Scopus

    PubMed

  5. OLITIS CYSTICA PROFUNDA DIAGNOSED BY ESD

    YAMADA Kentaro, YAMAMURA Takeshi, NAKAMURA Masanao, MAEDA Keiko, SAWADA Tsunaki, ISHIKAWA Eri, KAJIKAWA Go, HASEGAWA Issei, YOKOI Takio, KAWASHIMA Hiroki

    GASTROENTEROLOGICAL ENDOSCOPY   Vol. 66 ( 3 ) page: 279 - 285   2024

     More details

    Language:Japanese   Publisher:Japan Gastroenterological Endoscopy Society  

    <p>A 46-year-old female patient presented to our hospital for close examination and treatment after a rectal mass was observed during a CS performed at another hospital. On repeat CS, we observed a 10-mm, submucosal, tumor-like mass in the lower rectum. EUS showed a 10-mm hypoechoic tumor located in the submucosa. We performed ESD because the boring biopsy specimens showed nonspecific pathologic findings. Pathological examination of the resected lesion confirmed the diagnosis of colitis cystica profunda.</p>

    DOI: 10.11280/gee.66.279

    Scopus

    CiNii Research

▼display all

MISC 16

  1. 特集 IBD診療-ますます増えた薬剤の選択とさらなる進化の展望 1.治療薬の使い分けの総論と各論(4)中等症UCにおけるバイオ製剤/JAK阻害薬の使い分け-抗IL-23抗体も含めて

    中村 正直, 山村 健史, 前田 啓子, 澤田 つな騎, 石川 恵里, 川嶋 啓揮

    臨床消化器内科   Vol. 39 ( 2 ) page: 140 - 146   2024.1

     More details

    Publisher:日本メディカルセンター  

    DOI: 10.19020/cg.0000002926

    CiNii Research

  2. 腸管上皮細胞は、病原体の接着を認識し、エンドソームの機能調節を介して、侵入を阻害する

    前田啓子, Wayne I Lencer

    実験医学     2022.8

  3. 特集 小腸内視鏡が変えた疾患マネージメント 小腸疾患に対するアプローチ

    中村 正直, 大宮 直木, 山村 健史, 前田 啓子, 澤田 つな騎, 石川 恵里

    消化器内視鏡   Vol. 33 ( 12 ) page: 1792 - 1798   2021.12

     More details

    Publisher:(株)東京医学社  

    DOI: 10.24479/j02312.2022082023

    CiNii Research

  4. Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis Reviewed

    Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Ohashi A, Kajikawa G, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Fujishiro M

    Internal medicine (Tokyo, Japan)     2020.7

     More details

    Language:English  

    DOI: 10.2169/internalmedicine.5302-20

    PubMed

  5. Use of Immunostaining for the diagnosis of Lymphovascular invasion in superficial Barrett's esophageal adenocarcinoma. Reviewed

    Hosono I, Miyahara R, Furukawa K, Funasaka K, Sawada T, Maeda K, Yamamura T, Ishikawa T, Ohno E, Nakamura M, Kawashima H, Yokoi T, Tsukamoto T, Hirooka Y, Fujishiro M

    BMC gastroenterology   Vol. 20 ( 1 ) page: 175   2020.6

     More details

    Language:English  

    DOI: 10.1186/s12876-020-01319-7

    PubMed

▼display all

Presentations 8

  1. PARD6Bによる腸管上皮細胞の新たな防御機構の同定

    前田啓子, 中村正直, 藤城光弘

    消化器病学会総会 

     More details

    Event date: 2019.5

    Language:English   Presentation type:Symposium, workshop panel (public)  

    Venue:石川県   Country:Japan  

  2. Innate Host Defense at Mucosal Surfaces by Rapid Degradation of Pard6B and Apkc to Deplete the Apical Endosome International conference

    Keiko Maeda, Nicholas Zachos, and Wayne I Lencer

     More details

    Event date: 2018.6

    Language:English   Presentation type:Oral presentation (general)  

    Country:United States  

  3. Only the PARD6B Paralogue of the PARD6 Polarity Protein Family Regulates the Apical Endosomal Compartment of Canine MDCK Epithelial Cells International conference

    Keiko Maeda, Wayne I Lencer

     More details

    Event date: 2017.5

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  4. クローン病におけるustekinumabの治療効果および予後予測因子の検討

    村手健太郎、前田啓子、藤代光弘

    日本消化器病学会総会  2021.4 

  5. 潰瘍性大腸炎の内視鏡的活動性と粘膜治癒を反映するバイオマーカーの同定

    前田啓子, 中村正直, 藤代光弘

    日本消化器病学会総会  2022.4.22 

▼display all

Research Project for Joint Research, Competitive Funding, etc. 8

  1. 腸管上皮細胞の抗原認識機構の解明と炎症性腸疾患への治療応用

    2023.4 - 2025.3

    日本炎症性腸疾患学会 

  2. 腸管上皮細胞の防御機構の解明と治療応用

    2023.4 - 2025.3

    日本女医会 

  3. 炎症性腸疾患の多様化を見据えた新規インフラマソーム標的治療法の開発

    2021.4 - 2022.3

    国立研究開発法人 日本医療研究開発機構  国立研究開発法人 日本医療研究開発機構 

      More details

    Authorship:Principal investigator 

  4. Disentangling underlying mechanism of cross-talk between the gut-brain axis to influence brain behavior functionality

    国立研究開発法人 日本医療研究開発機構 

      More details

    Authorship:Principal investigator 

  5. 新しい動物モデルを用いた炎症性腸疾患の病態解明と 新規治療法の探索

    公益財団法人豊秋奨学会 

      More details

    Authorship:Principal investigator 

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 2

  1. Elucidation of the cell-autonomous host defense at mucosal ssurfaces in rotavirus infection

    2024.9 - 2026.3

    国立研究開発法人 日本医療研究開発機構 

  2. 炎症性腸疾患の多様化を見据えた新規インフラマソーム標的治療法の開発

    Grant number:21K15920  2021.4 - 2024.3

    日本学術振興会  科学研究費助成事業  若手研究

    前田 啓子

      More details

    Authorship:Principal investigator 

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

    近年、IBD患者の急増とともに、既存治療に対する一次、二次無効を呈する難治例が増加し、病態に応じた治療戦略の確立が急務となっている。その病態には粘膜免疫の破綻、腸内細菌叢の関与とともに、両者を制御するインフラマソーム経路の重要性が認識されてきている。申請者は、治療抵抗性のIBD患者の血液、腸管組織においてインフラマソーム関連サイトカインの発現が上昇することを見出した。IL-18が高発現する患者群の粘膜関連細菌叢、NLRP3、NLRC4遺伝子変異、臨床情報を解析し、特徴を明らかにすることは、IL-18が病態の主軸となる患者群の特定、そして病態に応じた治療応用につながると考えられる。
    近年、炎症性腸疾患(IBD)患者の急増とともに、既存治療に対する一次、二次無効を呈する難治例が増加し、病態に応じた治療戦略の確立が急務となっている。その病態には粘膜免疫の破綻、腸内細菌叢の関与とともに、両者を制御するインフラマソーム経路の重要性が認識されてきている。研究代表者は、治療抵抗性のIBD患者の血液、腸管組織においてインフラマソーム関連サイトカインであるインターロイキン-18(IL-18)の発現の上昇を見出した。加えて、抗マウスIL-18中和抗体の投与により、腸内細菌叢の変化、Th1経路の抑制を介して、IBDモデルマウスの腸炎が改善するという知見を得た。研究代表者らは、これらの結果をもとに、より高い特異性・より長い半減期を持つ抗ヒト活性型IL-18モノクローナル中和抗体を開発した。抗ヒトIL-18中和抗体はマウスIL-18と結合し、マウス細胞株P815 において、IL-18にて産生が誘導されるCXCL-2の分泌を、用量依存的に抑制する結果を得ている 。マウスIL-18機能も抑制することから、IBDモデルマウスを用いた評価が可能である。また、抗ヒトIL-18中和抗体は、カニクイザルIL-18と結合することも同定している。
    今年度は、抗IL-18抗体の投与にて2種類の腸炎モデルマウスの炎症を抑制することを同定した。また、既存治療との併用にてより優位に腸炎抑制効果があることを見出した。現在は、抗ヒトIL-18抗体の炎症抑制効果をヒト腸管オルガノイド、カニクイザルを用いて実験を行い、抗ヒトIL-18抗体の安全性の確認、有効容量の設定を検討している。
    作成した抗活性型IL-18抗体は、2種類の腸炎モデルマウスへの投与を行ったところ、有意な腸炎抑制効果を認めた。腸炎抑制の機序としては、腸管上皮細胞のバリア機能の改善、Th1経路の抑制、腸内細菌叢の変化を誘導することを同定した。また、既存治療との併用にて相乗して腸炎抑制効果を認めることを同定した。
    <BR>
    現在は、抗ヒトIL-18抗体の安全性、腸炎抑制効果の評価のため、ヒトと活性型IL-18の断端が同じであるカニクイザルに投与を行い、安全性の評価、また腸炎モデルでの治療効果について検討を行う予定である。おおむね計画通りに進行している。
    今後は抗ヒトIL-18抗体の炎症抑制効果をヒト腸管オルガノイド、カニクイザルを用いて実験を行い、抗ヒトIL-18抗体の安全性の確認、有効容量の設定を行う、また、当院のIBDデータベースを利用した血清IL-18高発現群の予後、臨床的特徴、インフラマソームの構成分子であるNLRP3、NLRC4遺伝子変異、粘膜関連細菌叢の解析を行う。

Industrial property rights 2

  1. 炎症性腸疾患の活動性バイオマーカーの同定

    前田啓子, 中村正直, 石上雅敏

     More details

    Application no:特願2022-036955  Date applied:2022.1

  2. 間葉系幹細胞とペリサイトの新規マーカーの同定

    榎本篤、前田啓子、高橋雅英

     More details

    Application no:2015153712  Date applied:2015

    Country of applicant:Domestic